A Chinese listed pharmaceutical company under probe over a vaccine scandal has been involved in several cases of bribery in recent years, even as its profits soared, public records show.
Changchun Changsheng Biotechnology Co and its parent company, Changsheng Biotech, have been mentioned in at least 10 bribery-related cases in the past decade, according to China Judgment Online, a web-accessible database that discloses court rulings. China Daily searched the database on Monday (July 23).
The judgments in the criminal cases say the company’s employees or distributors paid money to people responsible for buying vaccines, including those working in hospitals or disease control departments at the county or city level, to be given priority in vaccine purchases.
For example, a court in Ningling county, Henan province, ruled in September that a man surnamed Song, who worked for a disease prevention and control centre in Suixian county, had accepted bribes of more than 1 million yuan (S$200,000) from several vaccine makers or agencies since July 2011, including 124,680 yuan from Changchun Changsheng Biotechnology.
Song was sentenced to 18 months in prison for bribery and fined 200,000 yuan, the court information said.
In November, Xiashan District People’s Court in Zhanjiang, Guangdong province, sentenced a woman in charge of vaccinations at a hospital to 18 months with an 18-month reprieve for bribery after she received illicit profits from the company’s chickenpox vaccine agency.
But in all cases, the companies that paid the bribes were rarely prosecuted, as the amount of money offered was not enough to draw a harsher penalty under the law, and the company was not the only one to offer a bribe.